News headlines about Psychemedics Corporation (NASDAQ:PMD) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Psychemedics Corporation earned a news sentiment score of 0.50 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 90 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the next several days.
Psychemedics Corporation (NASDAQ PMD) opened at 27.15 on Wednesday. The firm has a market cap of $148.24 million, a PE ratio of 18.22 and a beta of 1.00. The company’s 50-day moving average is $21.83 and its 200 day moving average is $21.65. Psychemedics Corporation has a one year low of $13.81 and a one year high of $27.45.
Psychemedics Corporation (NASDAQ:PMD) last announced its quarterly earnings results on Tuesday, April 25th. The company reported $0.27 EPS for the quarter. The business had revenue of $10.21 million during the quarter. Psychemedics Corporation had a net margin of 19.29% and a return on equity of 56.76%. Equities analysts anticipate that Psychemedics Corporation will post $0.93 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Positive News Coverage Very Likely to Impact Psychemedics Corporation (NASDAQ:PMD) Stock Price” was reported by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/positive-news-coverage-very-likely-to-impact-psychemedics-corporation-nasdaqpmd-stock-price/1180355.html.
Psychemedics Corporation Company Profile
Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment.
Receive News & Ratings for Psychemedics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics Corporation and related companies with our FREE daily email newsletter.